{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:38:58Z","timestamp":1787020738199,"version":"build-2736575974"},"reference-count":205,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8230153385"],"award-info":[{"award-number":["8230153385"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Henan Provincial Traditional Chinese Medicine Scientific Research Special Project","award":["2025ZY1031"],"award-info":[{"award-number":["2025ZY1031"]}]},{"name":"Joint Fund Project of Henan Province Science and Technology R & D Plan","award":["242301420081"],"award-info":[{"award-number":["242301420081"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease closely associated with metabolic dysregulation, exhibiting a complex and multifactorial pathogenesis. Recent studies demonstrate that impaired intestinal barrier function, intestinal immune barrier dysfunction, gut microbiota dysbiosis, and their associated metabolites collectively promote energy metabolism dysregulation and systemic inflammatory responses via the gut-liver axis. These interconnected processes represent key drivers in the pathogenesis and progression of NAFLD. Notably, Traditional Chinese Medicine (TCM) offers a promising therapeutic approach for NAFLD by holistically modulating intestinal barrier function, immune responses, and gut microbiota composition via multiple targets and pathways, thereby ameliorating gut dysbiosis and its downstream metabolic and inflammatory sequelae. This review systematically synthesizes the established relationship between NAFLD and intestinal barrier dysfunction. It critically evaluates current research progress on TCM interventions\u2014including single herbs, bioactive constituents, and compound formulas\u2014that target the intestinal barrier for NAFLD management. Key mechanistic insights into TCM efficacy are summarized, focusing on the repair of the intestinal mucosal barrier, modulation of bile acid metabolism and gut microbiota composition, and enhancement of intestinal immune barrier function. Future research should prioritize elucidating the specific molecular mechanisms underpinning TCM-mediated intestinal barrier regulation and strengthening clinical validation, ultimately advancing the scientific foundation for TCM-based NAFLD therapeutics.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1186\/s13020-025-01311-x","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T10:43:14Z","timestamp":1767955394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Targeting the intestinal barrier with traditional Chinese medicine for non-alcoholic fatty liver disease: mechanistic insights and therapeutic perspectives"],"prefix":"10.1186","volume":"21","author":[{"given":"Xinyue","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuntian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaibing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"1311_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851\u201361. https:\/\/doi.org\/10.1016\/S2468-1253(22)00165-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1311_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039.","journal-title":"J Hepatol"},{"key":"1311_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018. https:\/\/doi.org\/10.1038\/s41591-018-0104-9.","journal-title":"Nat Med"},{"key":"1311_CR4","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1021\/acs.jafc.9b00080","volume":"67","author":"Y Cui","year":"2019","unstructured":"Cui Y, Wang Q, Chang R, Zhou X, Xu C. Intestinal barrier function-non-alcoholic fatty liver disease interactions and possible role of gut microbiota. J Agric Food Chem. 2019;67:2754\u201362. https:\/\/doi.org\/10.1021\/acs.jafc.9b00080.","journal-title":"J Agric Food Chem"},{"key":"1311_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176402","volume":"21","author":"B Allam-Ndoul","year":"2020","unstructured":"Allam-Ndoul B, Castonguay-Paradis S, Veilleux A. Gut microbiota and intestinal trans-epithelial permeability. Int J Mol Sci. 2020;21:6402. https:\/\/doi.org\/10.3390\/ijms21176402.","journal-title":"Int J Mol Sci"},{"key":"1311_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3390\/biomedicines10010083","volume":"10","author":"P Portincasa","year":"2021","unstructured":"Portincasa P, Bonfrate L, Khalil M, Angelis MD, Calabrese FM, D\u2019Amato M, et al. Intestinal barrier and permeability in health, obesity and NAFLD. Biomedicines. 2021;10:83. https:\/\/doi.org\/10.3390\/biomedicines10010083.","journal-title":"Biomedicines"},{"key":"1311_CR7","doi-asserted-by":"publisher","first-page":"H1227","DOI":"10.1152\/ajpheart.00612.2020","volume":"319","author":"CV Lewis","year":"2020","unstructured":"Lewis CV, Taylor WR. Intestinal barrier dysfunction as a therapeutic target for cardiovascular disease. Am J Physiol Heart Circ Physiol. 2020;319:H1227\u201333. https:\/\/doi.org\/10.1152\/ajpheart.00612.2020.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1311_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/19490976.2019.1638722","volume":"11","author":"A Parker","year":"2020","unstructured":"Parker A, Fonseca S, Carding SR. Gut microbes and metabolites as modulators of blood-brain barrier integrity and brain health. Gut Microbes. 2020;11:135\u201357. https:\/\/doi.org\/10.1080\/19490976.2019.1638722.","journal-title":"Gut Microbes"},{"key":"1311_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.863779","volume":"12","author":"Q Che","year":"2022","unstructured":"Che Q, Luo T, Shi J, He Y, Xu D-L. Mechanisms by which traditional Chinese medicines influence the intestinal flora and intestinal barrier. Front Cell Infect Microbiol. 2022;12:863779. https:\/\/doi.org\/10.3389\/fcimb.2022.863779.","journal-title":"Front Cell Infect Microbiol"},{"key":"1311_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0126-x","volume":"50","author":"C Chelakkot","year":"2018","unstructured":"Chelakkot C, Ghim J, Ryu SH. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med. 2018;50:1\u20139. https:\/\/doi.org\/10.1038\/s12276-018-0126-x.","journal-title":"Exp Mol Med"},{"key":"1311_CR11","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41575-022-00675-x","volume":"19","author":"JK Gustafsson","year":"2022","unstructured":"Gustafsson JK, Johansson MEV. The role of goblet cells and mucus in intestinal homeostasis. Nat Rev Gastroenterol Hepatol. 2022;19:785\u2013803. https:\/\/doi.org\/10.1038\/s41575-022-00675-x.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1311_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrgastro.2016.169","volume":"14","author":"MA Odenwald","year":"2017","unstructured":"Odenwald MA, Turner JR. The intestinal epithelial barrier: a therapeutic target? Nat Rev Gastroenterol Hepatol. 2017;14:9\u201321. https:\/\/doi.org\/10.1038\/nrgastro.2016.169.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1311_CR13","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1159\/000233282","volume":"27","author":"L Shen","year":"2009","unstructured":"Shen L, Su L, Turner JR. Mechanisms and functional implications of intestinal barrier defects. Dig Dis. 2009;27:443\u20139. https:\/\/doi.org\/10.1159\/000233282.","journal-title":"Dig Dis"},{"key":"1311_CR14","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.3390\/ijms22052506","volume":"22","author":"T Paradis","year":"2021","unstructured":"Paradis T, B\u00e8gue H, Basmaciyan L, Dalle F, Bon F. Tight junctions as a key for pathogens invasion in intestinal epithelial cells. Int J Mol Sci. 2021;22:2506. https:\/\/doi.org\/10.3390\/ijms22052506.","journal-title":"Int J Mol Sci"},{"key":"1311_CR15","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1007\/s00018-008-8281-1","volume":"65","author":"F van Roy","year":"2008","unstructured":"van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci. 2008;65:3756\u201388. https:\/\/doi.org\/10.1007\/s00018-008-8281-1.","journal-title":"Cell Mol Life Sci"},{"key":"1311_CR16","doi-asserted-by":"publisher","first-page":"13589","DOI":"10.1074\/jbc.M114.554709","volume":"289","author":"S Pokutta","year":"2014","unstructured":"Pokutta S, Choi H-J, Ahlsen G, Hansen SD, Weis WI. Structural and thermodynamic characterization of cadherin\u00b7\u03b2-catenin\u00b7\u03b1-catenin complex formation. J Biol Chem. 2014;289:13589\u2013601. https:\/\/doi.org\/10.1074\/jbc.M114.554709.","journal-title":"J Biol Chem"},{"key":"1311_CR17","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1091\/mbc.E20-12-0775","volume":"32","author":"A Raya-Sandino","year":"2021","unstructured":"Raya-Sandino A, Luissint A-C, Kusters DHM, Narayanan V, Flemming S, Garcia-Hernandez V, et al. Regulation of intestinal epithelial intercellular adhesion and barrier function by desmosomal cadherin desmocollin-2. Mol Biol Cell. 2021;32:753\u201368. https:\/\/doi.org\/10.1091\/mbc.E20-12-0775.","journal-title":"Mol Biol Cell"},{"key":"1311_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111359","volume":"22","author":"P Serek","year":"2021","unstructured":"Serek P, Oleksy-Wawrzyniak M. The effect of bacterial infections, probiotics and zonulin on intestinal barrier integrity. Int J Mol Sci. 2021;22:11359. https:\/\/doi.org\/10.3390\/ijms222111359.","journal-title":"Int J Mol Sci"},{"key":"1311_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1053\/j.sempedsurg.2004.10.025","volume":"14","author":"DJ Hackam","year":"2005","unstructured":"Hackam DJ, Upperman JS, Grishin A, Ford HR. Disordered enterocyte signaling and intestinal barrier dysfunction in the pathogenesis of necrotizing enterocolitis. Semin Pediatr Surg. 2005;14:49\u201357. https:\/\/doi.org\/10.1053\/j.sempedsurg.2004.10.025.","journal-title":"Semin Pediatr Surg"},{"key":"1311_CR20","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3745135","volume":"2022","author":"X Li","year":"2022","unstructured":"Li X, Wang C, Zhu J, Lin Q, Yu M, Wen J, et al. Sodium butyrate ameliorates oxidative stress-induced intestinal epithelium barrier injury and mitochondrial damage through AMPK-mitophagy pathway. Oxid Med Cell Longev. 2022;2022:3745135. https:\/\/doi.org\/10.1155\/2022\/3745135.","journal-title":"Oxid Med Cell Longev"},{"key":"1311_CR21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41419-021-03896-1","volume":"12","author":"S Sun","year":"2021","unstructured":"Sun S, Duan Z, Wang X, Chu C, Yang C, Chen F, et al. Neutrophil extracellular traps impair intestinal barrier functions in sepsis by regulating TLR9-mediated endoplasmic reticulum stress pathway. Cell Death Dis. 2021;12:606. https:\/\/doi.org\/10.1038\/s41419-021-03896-1.","journal-title":"Cell Death Dis"},{"key":"1311_CR22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/ame2.12262","volume":"5","author":"Q Fu","year":"2022","unstructured":"Fu Q, Song T, Ma X, Cui J. Research progress on the relationship between intestinal microecology and intestinal bowel disease. Anim Model Exp Med. 2022;5:297\u2013310. https:\/\/doi.org\/10.1002\/ame2.12262.","journal-title":"Anim Model Exp Med"},{"key":"1311_CR23","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s11427-023-2353-0","volume":"67","author":"W Jia","year":"2024","unstructured":"Jia W, Li Y, Cheung KCP, Zheng X. Bile acid signaling in the regulation of whole body metabolic and immunological homeostasis. Sci China Life Sci. 2024;67:865\u201378. https:\/\/doi.org\/10.1007\/s11427-023-2353-0.","journal-title":"Sci China Life Sci"},{"key":"1311_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113577","volume":"154","author":"S Zhou","year":"2022","unstructured":"Zhou S, You H, Qiu S, Yu D, Bai Y, He J, et al. A new perspective on NAFLD: focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPAR\u03b1) and farnesoid X receptor (FXR). Biomed Pharmacother. 2022;154:113577. https:\/\/doi.org\/10.1016\/j.biopha.2022.113577.","journal-title":"Biomed Pharmacother"},{"key":"1311_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.febslet.2007.11.015","volume":"582","author":"Y Zhang","year":"2008","unstructured":"Zhang Y, Edwards PA. FXR signaling in metabolic disease. FEBS Lett. 2008;582:10\u20138. https:\/\/doi.org\/10.1016\/j.febslet.2007.11.015.","journal-title":"FEBS Lett"},{"key":"1311_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.apsb.2015.01.004","volume":"5","author":"L Ding","year":"2015","unstructured":"Ding L, Yang L, Wang Z, Huang W. Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharm Sin B. 2015;5:135\u201344. https:\/\/doi.org\/10.1016\/j.apsb.2015.01.004.","journal-title":"Acta Pharm Sin B"},{"key":"1311_CR27","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.1016\/j.apsb.2021.05.023","volume":"11","author":"D Rizzolo","year":"2021","unstructured":"Rizzolo D, Kong B, Taylor RE, Brinker A, Goedken M, Buckley B, et al. Bile acid homeostasis in female mice deficient in Cyp7a1 and Cyp27a1. Acta Pharm Sin B. 2021;11:3847\u201356. https:\/\/doi.org\/10.1016\/j.apsb.2021.05.023.","journal-title":"Acta Pharm Sin B"},{"key":"1311_CR28","doi-asserted-by":"publisher","first-page":"365","DOI":"10.16288\/j.yczz.19-011","volume":"41","author":"X Liu","year":"2019","unstructured":"Liu X, Wang Y. [an overview of bile acid synthesis and its physiological and pathological functions]. Yi Chuan. 2019;41:365\u201374. https:\/\/doi.org\/10.16288\/j.yczz.19-011.","journal-title":"Yi Chuan"},{"key":"1311_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.151453","volume":"751","author":"N Kiaei","year":"2025","unstructured":"Kiaei N, Malik A, Idahosa SO, Lee KK, Endo-Umeda K, Makishima M, et al. Python-derived 16\u03b1-hydroxylated bile acid, pythocholic acid is a ligand for TGR5, not farnesoid X receptors and vitamin D receptors. Biochem Biophys Res Commun. 2025;751:151453. https:\/\/doi.org\/10.1016\/j.bbrc.2025.151453.","journal-title":"Biochem Biophys Res Commun"},{"key":"1311_CR30","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41579-022-00805-x","volume":"21","author":"SL Collins","year":"2023","unstructured":"Collins SL, Stine JG, Bisanz JE, Okafor CD, Patterson AD. Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nat Rev Microbiol. 2023;21:236\u201347. https:\/\/doi.org\/10.1038\/s41579-022-00805-x.","journal-title":"Nat Rev Microbiol"},{"key":"1311_CR31","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.chom.2023.12.015","volume":"32","author":"T Li","year":"2024","unstructured":"Li T, Ding N, Guo H, Hua R, Lin Z, Tian H, et al. A gut microbiota-bile acid axis promotes intestinal homeostasis upon aspirin-mediated damage. Cell Host Microbe. 2024;32:191-208.e9. https:\/\/doi.org\/10.1016\/j.chom.2023.12.015.","journal-title":"Cell Host Microbe"},{"key":"1311_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cphy.c190007","volume":"10","author":"AL Ticho","year":"2019","unstructured":"Ticho AL, Malhotra P, Dudeja PK, Gill RK, Alrefai WA. Intestinal absorption of bile acids in health and disease. Compr Physiol. 2019;10:21\u201356. https:\/\/doi.org\/10.1002\/cphy.c190007.","journal-title":"Compr Physiol"},{"key":"1311_CR33","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s10482-020-01474-7","volume":"113","author":"EZ Gomaa","year":"2020","unstructured":"Gomaa EZ. Human gut microbiota\/microbiome in health and diseases: a review. Antonie Van Leeuwenhoek. 2020;113:2019\u201340. https:\/\/doi.org\/10.1007\/s10482-020-01474-7.","journal-title":"Antonie Van Leeuwenhoek"},{"key":"1311_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00974-4","author":"K Hou","year":"2022","unstructured":"Hou K, Wu ZX, Chen XY, Wang JQ, et al. Microbiota in health and diseases Signal transduction and targeted therapy. Signal Transduct Target Ther. 2022. https:\/\/doi.org\/10.1038\/s41392-022-00974-4.","journal-title":"Signal Transduct Target Ther"},{"key":"1311_CR35","doi-asserted-by":"publisher","first-page":"8787","DOI":"10.3748\/wjg.v21.i29.8787","volume":"21","author":"SM Jandhyala","year":"2015","unstructured":"Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. World J Gastroenterol. 2015;21:8787\u2013803. https:\/\/doi.org\/10.3748\/wjg.v21.i29.8787.","journal-title":"World J Gastroenterol"},{"key":"1311_CR36","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.clnu.2019.05.014","volume":"39","author":"Y Xiao","year":"2020","unstructured":"Xiao Y, Zhao J, Zhang H, Zhai Q, Chen W. Mining lactobacillus and bifidobacterium for organisms with long-term gut colonization potential. Clin Nutr. 2020;39:1315\u201323. https:\/\/doi.org\/10.1016\/j.clnu.2019.05.014.","journal-title":"Clin Nutr"},{"key":"1311_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/imr.12567","volume":"279","author":"JM Pickard","year":"2017","unstructured":"Pickard JM, Zeng MY, Caruso R, N\u00fa\u00f1ez G. Gut microbiota: role in pathogen colonization, immune responses, and inflammatory disease. Immunol Rev. 2017;279:70\u201389. https:\/\/doi.org\/10.1111\/imr.12567.","journal-title":"Immunol Rev"},{"key":"1311_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/nu15092211","author":"W Fusco","year":"2023","unstructured":"Fusco W, Lorenzo MB, Cintoni M, Porcari S, et al. Short-chain fatty-acid-producing bacteria: Key components of the human gut microbiota. Nutrients. 2023. https:\/\/doi.org\/10.3390\/nu15092211.","journal-title":"Nutrients"},{"key":"1311_CR39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1017\/S0029665120006916","volume":"80","author":"C Martin-Gallausiaux","year":"2021","unstructured":"Martin-Gallausiaux C, Marinelli L, Blotti\u00e8re HM, Larraufie P, Lapaque N. SCFA: mechanisms and functional importance in the gut. Proc Nutr Soc. 2021;80:37\u201349. https:\/\/doi.org\/10.1017\/S0029665120006916.","journal-title":"Proc Nutr Soc"},{"key":"1311_CR40","doi-asserted-by":"publisher","first-page":"282","DOI":"10.2174\/156652408784533779","volume":"8","author":"F Lutgendorff","year":"2008","unstructured":"Lutgendorff F, Akkermans LMA, S\u00f6derholm JD. The role of microbiota and probiotics in stress-induced gastro-intestinal damage. Curr Mol Med. 2008;8:282\u201398. https:\/\/doi.org\/10.2174\/156652408784533779.","journal-title":"Curr Mol Med"},{"key":"1311_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.916824","volume":"13","author":"C Peng","year":"2022","unstructured":"Peng C, Li J, Miao Z, Wang Y, Wu S, Wang Y, et al. Early life administration of bifidobacterium bifidum BD-1 alleviates long-term colitis by remodeling the gut microbiota and promoting intestinal barrier development. Front Microbiol. 2022;13:916824. https:\/\/doi.org\/10.3389\/fmicb.2022.916824.","journal-title":"Front Microbiol"},{"key":"1311_CR42","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3390\/cells12050793","volume":"12","author":"J Wang","year":"2023","unstructured":"Wang J, Zhu N, Su X, Gao Y, Yang R. Gut-microbiota-derived metabolites maintain gut and systemic immune homeostasis. Cells. 2023;12:793. https:\/\/doi.org\/10.3390\/cells12050793.","journal-title":"Cells"},{"key":"1311_CR43","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41385-021-00389-4","volume":"14","author":"UM M\u00f6rbe","year":"2021","unstructured":"M\u00f6rbe UM, J\u00f8rgensen PB, Fenton TM, von Burg N, Riis LB, Spencer J, et al. Human gut-associated lymphoid tissues (GALT); diversity, structure, and function. Mucosal Immunol. 2021;14:793\u2013802. https:\/\/doi.org\/10.1038\/s41385-021-00389-4.","journal-title":"Mucosal Immunol"},{"key":"1311_CR44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/BF00310046","volume":"176","author":"R Pabst","year":"1987","unstructured":"Pabst R. The anatomical basis for the immune function of the gut. Anat Embryol (Berl). 1987;176:135\u201344. https:\/\/doi.org\/10.1007\/BF00310046.","journal-title":"Anat Embryol (Berl)"},{"issue":"1","key":"1311_CR45","doi-asserted-by":"publisher","first-page":"E86","DOI":"10.1111\/j.1749-6632.2010.05711.x","volume":"1207","author":"I Koboziev","year":"2010","unstructured":"Koboziev I, Karlsson F, Grisham MB. Gut-associated lymphoid tissue, T cell trafficking, and chronic intestinal inflammation. Ann N Y Acad Sci. 2010;1207(1):E86-93. https:\/\/doi.org\/10.1111\/j.1749-6632.2010.05711.x.","journal-title":"Ann N Y Acad Sci"},{"key":"1311_CR46","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.it.2024.01.006","volume":"45","author":"M Bemark","year":"2024","unstructured":"Bemark M, Pitcher MJ, Dionisi C, Spencer J. Gut-associated lymphoid tissue: a microbiota-driven hub of B cell immunity. Trends Immunol. 2024;45:211\u201323. https:\/\/doi.org\/10.1016\/j.it.2024.01.006.","journal-title":"Trends Immunol"},{"key":"1311_CR47","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.it.2018.04.002","volume":"39","author":"JM Allaire","year":"2018","unstructured":"Allaire JM, Crowley SM, Law HT, Chang S-Y, Ko H-J, Vallance BA. The intestinal epithelium: central coordinator of mucosal immunity. Trends Immunol. 2018;39:677\u201396. https:\/\/doi.org\/10.1016\/j.it.2018.04.002.","journal-title":"Trends Immunol"},{"key":"1311_CR48","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.immuni.2024.03.004","volume":"57","author":"T Kawai","year":"2024","unstructured":"Kawai T, Ikegawa M, Ori D, Akira S. Decoding toll-like receptors: recent insights and perspectives in innate immunity. Immunity. 2024;57:649\u201373. https:\/\/doi.org\/10.1016\/j.immuni.2024.03.004.","journal-title":"Immunity"},{"key":"1311_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179627","volume":"23","author":"Z Yang","year":"2022","unstructured":"Yang Z, Tang X, Wang K, Dai K, Chang Y-F, Du S, et al. Metal ion periplasmic-binding protein YfeA of glaesserella parasuis induces the secretion of pro-inflammatory cytokines of macrophages via MAPK and NF-\u03baB signaling through TLR2 and TLR4. Int J Mol Sci. 2022;23:9627. https:\/\/doi.org\/10.3390\/ijms23179627.","journal-title":"Int J Mol Sci"},{"key":"1311_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.05.001","author":"A Cerutti","year":"2008","unstructured":"Cerutti A, Rescigno M. The biology of intestinal immunoglobulin a responses. Immunity. 2008. https:\/\/doi.org\/10.1016\/j.immuni.2008.05.001.","journal-title":"Immunity"},{"key":"1311_CR51","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/2032057","volume":"2020","author":"Y Li","year":"2020","unstructured":"Li Y, Jin L, Chen T. The effects of secretory IgA in the mucosal immune system. Biomed Res Int. 2020;2020:2032057. https:\/\/doi.org\/10.1155\/2020\/2032057.","journal-title":"Biomed Res Int"},{"key":"1311_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594150","author":"S Mohammad","year":"2021","unstructured":"Mohammad S, Thiemermann C. Role of metabolic endotoxemia in systemic inflammation and potential interventions. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2020.594150.","journal-title":"Front Immunol"},{"key":"1311_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/nu14245335","author":"W Guo","year":"2022","unstructured":"Guo W, Ge X, Lu J, Xu X, Gao J, et al. Diet and risk of non-alcoholic fatty liver disease, cirrhosis, and liver cancer: A large prospective cohort study in UK biobank. Nutrients. 2022. https:\/\/doi.org\/10.3390\/nu14245335.","journal-title":"Nutrients"},{"key":"1311_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/cells10113164","author":"IJ Malesza","year":"2021","unstructured":"Malesza IJ, Malesza M, Walkowiak J, Mussin N, et al. High-fat, western-style diet, systemic inflammation, and gut microbiota: a narrative review. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10113164.","journal-title":"Cells"},{"key":"1311_CR55","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2020.10932","author":"Y Xie","year":"2020","unstructured":"Xie Y, Ding F, Di W, Lv Y, Xia F, Sheng Y, et al. Impact of a high-fat diet on intestinal stem cells and epithelial barrier function in middle-aged female mice. Mol Med Rep. 2020. https:\/\/doi.org\/10.3892\/mmr.2020.10932.","journal-title":"Mol Med Rep"},{"key":"1311_CR56","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s42255-020-0261-2","volume":"2","author":"J Todoric","year":"2020","unstructured":"Todoric J, Di Caro G, Reibe S, Henstridge DC, Green CR, Vrbanac A, et al. Fructose stimulated de novo lipogenesis is promoted by inflammation. Nat Metab. 2020;2:1034\u201345. https:\/\/doi.org\/10.1038\/s42255-020-0261-2.","journal-title":"Nat Metab"},{"key":"1311_CR57","first-page":"136","volume":"61","author":"D Xin","year":"2014","unstructured":"Xin D, Zong-Shun L, Bang-Mao W, Lu Z. Expression of intestinal tight junction proteins in patients with non-alcoholic fatty liver disease. Hepatogastroenterology. 2014;61:136\u201340.","journal-title":"Hepatogastroenterology"},{"key":"1311_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/nu12030699","volume":"12","author":"A Nier","year":"2020","unstructured":"Nier A, Huber Y, Labenz C, Michel M, Bergheim I, Schattenberg JM. Adipokines and endotoxemia correlate with hepatic steatosis in non-alcoholic fatty liver disease (NAFLD). Nutrients. 2020;12:699. https:\/\/doi.org\/10.3390\/nu12030699.","journal-title":"Nutrients"},{"key":"1311_CR59","doi-asserted-by":"publisher","first-page":"7524","DOI":"10.1002\/jcp.27513","volume":"234","author":"R-X Bai","year":"2019","unstructured":"Bai R-X, Xu Y-Y, Qin G, Chen Y-M, Wang H-F, Wang M, et al. Repression of TXNIP-NLRP3 axis restores intestinal barrier function via inhibition of myeloperoxidase activity and oxidative stress in nonalcoholic steatohepatitis. J Cell Physiol. 2019;234:7524\u201338. https:\/\/doi.org\/10.1002\/jcp.27513.","journal-title":"J Cell Physiol"},{"key":"1311_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01399","volume":"9","author":"J-H Peng","year":"2018","unstructured":"Peng J-H, Leng J, Tian H-J, Yang T, Fang Y, Feng Q, et al. Geniposide and chlorogenic acid combination ameliorates non-alcoholic steatohepatitis involving the protection on the gut barrier function in mouse induced by high-fat diet. Front Pharmacol. 2018;9:1399. https:\/\/doi.org\/10.3389\/fphar.2018.01399.","journal-title":"Front Pharmacol"},{"key":"1311_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2025.101777","author":"M Zhou","year":"2025","unstructured":"Zhou M, Lv J, Chen X, Shi Y, Chao G, Zhang S. From gut to liver Exploring the crosstalk between gut-liver axis and oxidative stress in metabolic dysfunction-associated steatotic liver disease. Ann Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.aohep.2025.101777.","journal-title":"Ann Hepatol"},{"key":"1311_CR62","doi-asserted-by":"publisher","DOI":"10.1042\/CS20220697","author":"J Gillard","year":"2023","unstructured":"Gillard J, Leclercq IA. Biological tuners to reshape the bile acid pool for therapeutic purposes in non-alcoholic fatty liver disease. Clin Sci. 2023. https:\/\/doi.org\/10.1042\/CS20220697.","journal-title":"Clin Sci"},{"key":"1311_CR63","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1080\/00365520701320463","volume":"42","author":"A M\u00fcnch","year":"2007","unstructured":"M\u00fcnch A, Str\u00f6m M, S\u00f6derholm JD. Dihydroxy bile acids increase mucosal permeability and bacterial uptake in human colon biopsies. Scand J Gastroenterol. 2007;42:1167\u201374. https:\/\/doi.org\/10.1080\/00365520701320463.","journal-title":"Scand J Gastroenterol"},{"key":"1311_CR64","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00043.2007","author":"F Raimondi","year":"2008","unstructured":"Raimondi F, Santoro P, Barone MV, Pappacoda S, Barretta ML, et al. Bile acids modulate tight junction structure and barrier function of caco-2 monolayers via EGFR activation. Am J Physiol Gastrointest Liver Physiol. 2008. https:\/\/doi.org\/10.1152\/ajpgi.00043.2007.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1311_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/cells12141888","author":"L Shi","year":"2023","unstructured":"Shi L, Jin L, Huang W. Bile acids, intestinal barrier dysfunction, and related diseases. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12141888.","journal-title":"Cells"},{"key":"1311_CR66","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.cmet.2012.04.004","volume":"15","author":"H-K Min","year":"2012","unstructured":"Min H-K, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 2012;15:665\u201374. https:\/\/doi.org\/10.1016\/j.cmet.2012.04.004.","journal-title":"Cell Metab"},{"key":"1311_CR67","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjad060","author":"Q Jiang","year":"2024","unstructured":"Jiang Q, Wang N, Lu S, Xiong J, Yuan Y, et al. Targeting hepatic ceruloplasmin mitigates nonalcoholic steatohepatitis by modulating bile acid metabolism. J Mol Cell Biol. 2024. https:\/\/doi.org\/10.1093\/jmcb\/mjad060.","journal-title":"J Mol Cell Biol"},{"key":"1311_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100387","volume":"4","author":"J Gillard","year":"2022","unstructured":"Gillard J, Clerbaux L-A, Nachit M, Sempoux C, Staels B, Bindels LB, et al. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice. JHEP Rep. 2022;4:100387. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100387.","journal-title":"JHEP Rep"},{"key":"1311_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155214","volume":"21","author":"J Chen","year":"2020","unstructured":"Chen J, Vitetta L. Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications. Int J Mol Sci. 2020;21:5214. https:\/\/doi.org\/10.3390\/ijms21155214.","journal-title":"Int J Mol Sci"},{"key":"1311_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.997018","volume":"12","author":"J Fang","year":"2022","unstructured":"Fang J, Yu C-H, Li X-J, Yao J-M, Fang Z-Y, Yoon S-H, et al. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications. Front Cell Infect Microbiol. 2022;12:997018. https:\/\/doi.org\/10.3389\/fcimb.2022.997018.","journal-title":"Front Cell Infect Microbiol"},{"key":"1311_CR71","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1053\/j.gastro.2020.01.031","volume":"158","author":"E Scorletti","year":"2020","unstructured":"Scorletti E, Afolabi PR, Miles EA, Smith DE, Almehmadi A, Alshathry A, et al. Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease. Gastroenterology. 2020;158:1597-1610.e7. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.031.","journal-title":"Gastroenterology"},{"key":"1311_CR72","doi-asserted-by":"publisher","DOI":"10.1002\/lipd.12410","author":"L Wang","year":"2024","unstructured":"Wang L, Xu J, You N, Shao L, Zhuang Z, Zhuo L, et al. Characteristics of intestinal flora in nonobese nonalcoholic fatty liver disease patients and the impact of ursodeoxycholic acid treatment on these features. Lipids. 2024. https:\/\/doi.org\/10.1002\/lipd.12410.","journal-title":"Lipids"},{"key":"1311_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1366744","volume":"15","author":"F Huang","year":"2024","unstructured":"Huang F, Lyu B, Xie F, Li F, Xing Y, Han Z, et al. From gut to liver: unveiling the differences of intestinal microbiota in NAFL and NASH patients. Front Microbiol. 2024;15:1366744. https:\/\/doi.org\/10.3389\/fmicb.2024.1366744.","journal-title":"Front Microbiol"},{"key":"1311_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242015272","author":"AV Korobeinikova","year":"2023","unstructured":"Korobeinikova AV, Zlobovskaya OA, Sheptulina AF, Ashniev GA, Bobrova MM, Yafarova AA, et al. Gut microbiota patterns in patients with non-alcoholic fatty liver disease: a comprehensive assessment using three analysis methods. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms242015272.","journal-title":"Int J Mol Sci"},{"key":"1311_CR75","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13646","author":"X Su","year":"2024","unstructured":"Su X, Chen S, Liu J, Feng Y, Han E, Hao X, et al. Composition of gut microbiota and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Obes Rev. 2024. https:\/\/doi.org\/10.1111\/obr.13646.","journal-title":"Obes Rev"},{"key":"1311_CR76","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/gutjnl-2019-319664","volume":"70","author":"X Zhang","year":"2021","unstructured":"Zhang X, Coker OO, Chu ES, Fu K, Lau HCH, Wang Y-X, et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut. 2021;70:761\u201374. https:\/\/doi.org\/10.1136\/gutjnl-2019-319664.","journal-title":"Gut"},{"key":"1311_CR77","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1136\/gut.2008.165886","volume":"58","author":"PD Cani","year":"2009","unstructured":"Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58:1091\u2013103. https:\/\/doi.org\/10.1136\/gut.2008.165886.","journal-title":"Gut"},{"key":"1311_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11082059","author":"Z Li","year":"2023","unstructured":"Li Z, Yuan H, Chu H, Yang L. The crosstalk between gut microbiota and bile acids promotes the development of non-alcoholic fatty liver disease. Microorganisms. 2023. https:\/\/doi.org\/10.3390\/microorganisms11082059.","journal-title":"Microorganisms"},{"key":"1311_CR79","doi-asserted-by":"publisher","first-page":"6862","DOI":"10.1038\/s41467-022-34671-1","volume":"13","author":"Y Lei","year":"2022","unstructured":"Lei Y, Tang L, Chen Q, Wu L, He W, Tu D, et al. Disulfiram ameliorates nonalcoholic steatohepatitis by modulating the gut microbiota and bile acid metabolism. Nat Commun. 2022;13:6862. https:\/\/doi.org\/10.1038\/s41467-022-34671-1.","journal-title":"Nat Commun"},{"key":"1311_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.761981","volume":"12","author":"Y Chen","year":"2021","unstructured":"Chen Y, Cui W, Li X, Yang H. Interaction between commensal bacteria, immune response and the intestinal barrier in inflammatory bowel disease. Front Immunol. 2021;12:761981. https:\/\/doi.org\/10.3389\/fimmu.2021.761981.","journal-title":"Front Immunol"},{"key":"1311_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.967410","volume":"13","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Zhang H, Yao Y, Zhang X, Guan Y, Zheng F. CD4+ T cell activation and inflammation in NASH-related fibrosis. Front Immunol. 2022;13:967410. https:\/\/doi.org\/10.3389\/fimmu.2022.967410.","journal-title":"Front Immunol"},{"key":"1311_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1337241","author":"K Liu","year":"2024","unstructured":"Liu K, Tang S, Liu C, Ma J, Cao X, Yang X, et al. Systemic immune-inflammatory biomarkers SII NLR PLR and LMR linked to non-alcoholic fatty liver disease risk. Front Immunol. 2024. https:\/\/doi.org\/10.3389\/fimmu.2024.1337241.","journal-title":"Front Immunol"},{"key":"1311_CR83","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jhep.2023.04.037","volume":"79","author":"E Kotsiliti","year":"2023","unstructured":"Kotsiliti E, Leone V, Schuehle S, Govaere O, Li H, Wolf MJ, et al. Intestinal B cells license metabolic T-cell activation in NASH microbiota\/antigen-independently and contribute to fibrosis by IgA-FcR signalling. J Hepatol. 2023;79:296\u2013313. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.037.","journal-title":"J Hepatol"},{"key":"1311_CR84","first-page":"306","volume":"125","author":"L Su","year":"2012","unstructured":"Su L, Wang J-H, Cong X, Wang L-H, Liu F, Xie X-W, et al. Intestinal immune barrier integrity in rats with nonalcoholic hepatic steatosis and steatohepatitis. Chin Med J (Engl). 2012;125:306\u201311.","journal-title":"Chin Med J (Engl)"},{"key":"1311_CR85","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","volume":"16","author":"K Kazankov","year":"2019","unstructured":"Kazankov K, J\u00f8rgensen SMD, Thomsen KL, M\u00f8ller HJ, Vilstrup H, George J, et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol. 2019;16:145\u201359. https:\/\/doi.org\/10.1038\/s41575-018-0082-x.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1311_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00558-8","author":"Y Wen","year":"2021","unstructured":"Wen Y, Lambrecht J, Ju C, Tacke F. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell Mol Immunol. 2021. https:\/\/doi.org\/10.1038\/s41423-020-00558-8.","journal-title":"Cell Mol Immunol"},{"key":"1311_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2022.166480","volume":"1868","author":"B Yang","year":"2022","unstructured":"Yang B, Luo W, Wang M, Tang Y, Zhu W, Jin L, et al. Macrophage-specific MyD88 deletion and pharmacological inhibition prevents liver damage in non-alcoholic fatty liver disease via reducing inflammatory response. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2022;1868:166480. https:\/\/doi.org\/10.1016\/j.bbadis.2022.166480.","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"key":"1311_CR88","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3760\/cma.j.issn.1007-3418.2017.02.011","volume":"25","author":"HT Hou","year":"2017","unstructured":"Hou HT, Qiu YM, Zhao HW, Li DH, Liu YT, Wang YZ, et al. effect of curcumin on intestinal mucosal mechanical barrier in rats with non-alcoholic fatty liver disease. Zhonghua Gan Zang Bing Za Zhi. 2017;25:134\u20138. https:\/\/doi.org\/10.3760\/cma.j.issn.1007-3418.2017.02.011.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"1311_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155924","volume":"133","author":"J Yan","year":"2024","unstructured":"Yan J, Nie Y, Chen X, Ding M, Zhang S. Mechanistic study of fructus aurantii (quzhou origin) in regulating ileal reg3g in the treatment for NASH. Phytomedicine. 2024;133:155924. https:\/\/doi.org\/10.1016\/j.phymed.2024.155924.","journal-title":"Phytomedicine"},{"key":"1311_CR90","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s12072-021-10138-1","volume":"15","author":"Y Xu","year":"2021","unstructured":"Xu Y, Wang N, Tan H-Y, Li S, Zhang C, Feng Y. Gut-liver axis modulation of panax notoginseng saponins in nonalcoholic fatty liver disease. Hepatol Int. 2021;15:350\u201365. https:\/\/doi.org\/10.1007\/s12072-021-10138-1.","journal-title":"Hepatol Int"},{"key":"1311_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105884","volume":"173","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Guo X, Xie C, Cao Z, Wang X, Liu L, et al. Unraveling the metabolic pathway of choline-TMA-TMAO: Effects of gypenosides and implications for the therapy of TMAO related diseases. Pharmacol Res. 2021;173:105884. https:\/\/doi.org\/10.1016\/j.phrs.2021.105884.","journal-title":"Pharmacol Res"},{"key":"1311_CR92","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1080\/13880209.2022.2126503","volume":"60","author":"S Shen","year":"2022","unstructured":"Shen S, Wang K, Zhi Y, Dong Y. Gypenosides counteract hepatic steatosis and intestinal barrier injury in rats with metabolic associated fatty liver disease by modulating the adenosine monophosphate activated protein kinase and toll-like receptor 4\/nuclear factor kappa B pathways. Pharm Biol. 2022;60:1949\u201359. https:\/\/doi.org\/10.1080\/13880209.2022.2126503.","journal-title":"Pharm Biol"},{"key":"1311_CR93","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3389\/fpls.2018.00846","volume":"9","author":"H Wang","year":"2018","unstructured":"Wang H, Ma D, Yang J, Deng K, Li M, Ji X, et al. An integrative volatile terpenoid profiling and transcriptomics analysis for gene mining and functional characterization of AvBPPS and AvPS involved in the monoterpenoid biosynthesis in amomum villosum. Front Plant Sci. 2018;9:846. https:\/\/doi.org\/10.3389\/fpls.2018.00846.","journal-title":"Front Plant Sci"},{"key":"1311_CR94","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3589874","volume":"2018","author":"S Lu","year":"2018","unstructured":"Lu S, Zhang T, Gu W, Yang X, Lu J, Zhao R, et al. Volatile oil of amomum villosum inhibits nonalcoholic fatty liver disease via the gut-liver axis. Biomed Res Int. 2018;2018:3589874. https:\/\/doi.org\/10.1155\/2018\/3589874.","journal-title":"Biomed Res Int"},{"key":"1311_CR95","first-page":"5203","volume":"8","author":"Y-C Wang","year":"2015","unstructured":"Wang Y-C, Jin Q-M, Kong W-Z, Chen J. Protective effect of salvianolic acid B on NASH rat liver through restoring intestinal mucosal barrier function. Int J Clin Exp Pathol. 2015;8:5203\u20139.","journal-title":"Int J Clin Exp Pathol"},{"key":"1311_CR96","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.2147\/DDDT.S378976","volume":"16","author":"S Gao","year":"2022","unstructured":"Gao S, Feng Q. The beneficial effects of geniposide on glucose and lipid metabolism: a review. Drug Des Devel Ther. 2022;16:3365\u201383. https:\/\/doi.org\/10.2147\/DDDT.S378976.","journal-title":"Drug Des Devel Ther"},{"key":"1311_CR97","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/bs.apha.2019.12.002","volume":"87","author":"M Miao","year":"2020","unstructured":"Miao M, Xiang L. Pharmacological action and potential targets of chlorogenic acid. Adv Pharmacol. 2020;87:71\u201388. https:\/\/doi.org\/10.1016\/bs.apha.2019.12.002.","journal-title":"Adv Pharmacol"},{"key":"1311_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2022.115457","volume":"296","author":"H Ye","year":"2022","unstructured":"Ye H, Ma S, Qiu Z, Huang S, Deng G, Li Y, et al. Poria cocos polysaccharides rescue pyroptosis-driven gut vascular barrier disruption in order to alleviates non-alcoholic steatohepatitis. J Ethnopharmacol. 2022;296:115457. https:\/\/doi.org\/10.1016\/j.jep.2022.115457.","journal-title":"J Ethnopharmacol"},{"key":"1311_CR99","doi-asserted-by":"publisher","DOI":"10.1039\/C4FO00739E","author":"H Li","year":"2015","unstructured":"Li H, Qiu P, Wang J, Niu C, Pan S. Effects of compound ginkgo biloba on intestinal permeability in rats with alcohol-induced liver injury. Food Funct. 2015. https:\/\/doi.org\/10.1039\/C4FO00739E.","journal-title":"Food Funct"},{"key":"1311_CR100","first-page":"1580","volume":"40","author":"H Li","year":"2015","unstructured":"Li H, Wang J, Niu C, Pan S. Intervention effect and mechanism of compound ginkgo biloba preparations on nonalcoholic fatty liver. Zhongguo Zhong Yao Za Zhi. 2015;40:1580\u20134.","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"1311_CR101","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1954\/j.cnki.cjcmm.20230317.401","volume":"48","author":"Y-X Xiang","year":"2023","unstructured":"Xiang Y-X, Huang Y-L, Zhou M, Zou J-J, Liu X, Liu Z-Y, et al. zuogui jiangtang qinggan formula improves glucolipid metabolism in type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease by regulating FoxO1\/MTP\/APOB signaling pathway. Zhongguo Zhong Yao Za Zhi. 2023;48:4438\u201345. https:\/\/doi.org\/10.1954\/j.cnki.cjcmm.20230317.401.","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"1311_CR102","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1954\/j.cnki.cjcmm.20220913.703","volume":"48","author":"J-J Zou","year":"2023","unstructured":"Zou J-J, Li H, Zhou M, Huang Q-Q, Wu Y-J, Yu R. zuogui jiangtang qinggan prescription promotes recovery of intestinal mucosal barrier in mice with type 2 diabetes mellitus and nonalcoholic fatty liver disease by improving intestinal flora homeostasis. Zhongguo Zhong Yao Za Zhi. 2023;48:525\u201333. https:\/\/doi.org\/10.1954\/j.cnki.cjcmm.20220913.703.","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"1311_CR103","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1342\/j.cnki.syfjx.20250894","volume":"31","author":"M Miaomiao","year":"2025","unstructured":"Miaomiao M, Zibo Y, Kaili C, Jun Z, Zixuan YU, Wei D. Modern clinical application and mechanism of action of chaihu guizhi ganjiangtang: a review zggx. Chin J Exp Tradit Med Formul. 2025;31:266\u201377. https:\/\/doi.org\/10.1342\/j.cnki.syfjx.20250894.","journal-title":"Chin J Exp Tradit Med Formul"},{"key":"1311_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.117841","volume":"326","author":"H Wu","year":"2024","unstructured":"Wu H, Lou T, Pan M, Wei Z, Yang X, Liu L, et al. Chaihu guizhi ganjiang decoction attenuates nonalcoholic steatohepatitis by enhancing intestinal barrier integrity and ameliorating PPAR\u03b1 mediated lipotoxicity. J Ethnopharmacol. 2024;326:117841. https:\/\/doi.org\/10.1016\/j.jep.2024.117841.","journal-title":"J Ethnopharmacol"},{"key":"1311_CR105","doi-asserted-by":"publisher","DOI":"10.2103\/apm-20-1613","author":"T Wang","year":"2021","unstructured":"Wang T, Song J, Hu J, Feng S, Zhang H, Wang H, et al. Efficacy and safety of huazhi rougan granule in the treatment of non-alcoholic fatty liver: A systematic review and meta-analysis. Ann Palliat Med. 2021. https:\/\/doi.org\/10.2103\/apm-20-1613.","journal-title":"Ann Palliat Med"},{"key":"1311_CR106","doi-asserted-by":"publisher","DOI":"10.2174\/0113862073290372240603090844","author":"P Xie","year":"2024","unstructured":"Xie P, Jin X, Li C, Lv K, Deng M. Huazhi rougan granule alleviates liver and intestinal damage in non-alcoholic fatty liver disease by regulating miR-122 expression and TLR4\/MyD88\/NF-\u03baB pathway activation. Comb Chem High Throughput Screen. 2024. https:\/\/doi.org\/10.2174\/0113862073290372240603090844.","journal-title":"Comb Chem High Throughput Screen"},{"key":"1311_CR107","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11081437","volume":"11","author":"E Jang","year":"2022","unstructured":"Jang E. Hyperoside as a potential natural product targeting oxidative stress in liver diseases. Antioxidants. 2022;11:1437. https:\/\/doi.org\/10.3390\/antiox11081437.","journal-title":"Antioxidants"},{"key":"1311_CR108","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jare.2021.06.001","volume":"34","author":"S Wang","year":"2021","unstructured":"Wang S, Sheng F, Zou L, Xiao J, Li P. Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism. J Adv Res. 2021;34:109\u201322. https:\/\/doi.org\/10.1016\/j.jare.2021.06.001.","journal-title":"J Adv Res"},{"key":"1311_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.106002","volume":"175","author":"Y Wan","year":"2022","unstructured":"Wan Y, Xia J, Xu J-F, Chen L, Yang Y, Wu J-J, et al. Nuciferine, an active ingredient derived from lotus leaf, lights up the way for the potential treatment of obesity and obesity-related diseases. Pharmacol Res. 2022;175:106002. https:\/\/doi.org\/10.1016\/j.phrs.2021.106002.","journal-title":"Pharmacol Res"},{"key":"1311_CR110","doi-asserted-by":"publisher","first-page":"12014","DOI":"10.1021\/acs.jafc.2c04817","volume":"70","author":"J Sun","year":"2022","unstructured":"Sun J, Fan J, Li T, Yan X, Jiang Y. Nuciferine protects against high-fat diet-induced hepatic steatosis via modulation of gut microbiota and bile acid metabolism in rats. J Agric Food Chem. 2022;70:12014\u201328. https:\/\/doi.org\/10.1021\/acs.jafc.2c04817.","journal-title":"J Agric Food Chem"},{"key":"1311_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155919","volume":"133","author":"Y Huang","year":"2024","unstructured":"Huang Y, Chen H, Chen J, Wu Q, Zhang W, Li D, et al. Yellow tea polysaccharides protect against non-alcoholic fatty liver disease via regulation of gut microbiota and bile acid metabolism in mice. Phytomedicine. 2024;133:155919. https:\/\/doi.org\/10.1016\/j.phymed.2024.155919.","journal-title":"Phytomedicine"},{"key":"1311_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119921","volume":"284","author":"D Li","year":"2021","unstructured":"Li D, Rui Y-X, Guo S-D, Luan F, Liu R, Zeng N. Ferulic acid: a review of its pharmacology, pharmacokinetics and derivatives. Life Sci. 2021;284:119921. https:\/\/doi.org\/10.1016\/j.lfs.2021.119921.","journal-title":"Life Sci"},{"key":"1311_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13111277","volume":"13","author":"Y Liang","year":"2024","unstructured":"Liang Y, Qi J, Yu D, Wang Z, Li W, Long F, et al. Ferulic acid alleviates lipid and bile acid metabolism disorders by targeting FASN and CYP7A1 in iron overload-treated mice. Antioxidants. 2024;13:1277. https:\/\/doi.org\/10.3390\/antiox13111277.","journal-title":"Antioxidants"},{"key":"1311_CR114","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1002\/ptr.6486","volume":"33","author":"H Yang","year":"2019","unstructured":"Yang H, Yang T, Heng C, Zhou Y, Jiang Z, Qian X, et al. Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db\/db mice. Phytother Res. 2019;33:3140\u201352. https:\/\/doi.org\/10.1002\/ptr.6486.","journal-title":"Phytother Res"},{"key":"1311_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.154703","volume":"113","author":"T Yang","year":"2023","unstructured":"Yang T, Wang Y, Cao X, Peng Y, Huang J, Chen L, et al. Targeting mTOR\/YY1 signaling pathway by quercetin through CYP7A1-mediated cholesterol-to-bile acids conversion alleviated type 2 diabetes mellitus induced hepatic lipid accumulation. Phytomedicine. 2023;113:154703. https:\/\/doi.org\/10.1016\/j.phymed.2023.154703.","journal-title":"Phytomedicine"},{"key":"1311_CR116","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3390\/molecules29050976","volume":"29","author":"H Xu","year":"2024","unstructured":"Xu H, Yuan M, Niu K, Yang W, Jiang M, Zhang L, et al. Involvement of bile acid metabolism and gut microbiota in the amelioration of experimental metabolism-associated fatty liver disease by nobiletin. Molecules. 2024;29:976. https:\/\/doi.org\/10.3390\/molecules29050976.","journal-title":"Molecules"},{"key":"1311_CR117","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.3390\/molecules29174080","volume":"29","author":"Y Deng","year":"2024","unstructured":"Deng Y, Wang J, Wu D, Qin L, He Y, Tan D. Gypensapogenin a-liposomes efficiently ameliorates hepatocellular lipid accumulation via activation of FXR receptor. Molecules. 2024;29:4080. https:\/\/doi.org\/10.3390\/molecules29174080.","journal-title":"Molecules"},{"key":"1311_CR118","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1159\/000493297","volume":"49","author":"D Zhong","year":"2018","unstructured":"Zhong D, Xie Z, Huang B, Zhu S, Wang G, Zhou H, et al. Ganoderma lucidum polysaccharide peptide alleviates hepatoteatosis via modulating bile acid metabolism dependent on FXR-SHP\/FGF. Cell Physiol Biochem. 2018;49:1163\u201379. https:\/\/doi.org\/10.1159\/000493297.","journal-title":"Cell Physiol Biochem"},{"key":"1311_CR119","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/965723","volume":"2013","author":"J Pan","year":"2013","unstructured":"Pan J, Wang M, Song H, Wang L, Ji G. The efficacy and safety of traditional Chinese medicine (jiang zhi granule) for nonalcoholic fatty liver: a multicenter, randomized, placebo-controlled study. Evid Based Complement Alternat Med. 2013;2013:965723. https:\/\/doi.org\/10.1155\/2013\/965723.","journal-title":"Evid Based Complement Alternat Med"},{"key":"1311_CR120","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12906-019-2641-2","volume":"19","author":"L Yang","year":"2019","unstructured":"Yang L, Zhou Y, Song H, Zheng P. Jiang-zhi granules decrease sensitivity to low-dose CCl4 induced liver injury in NAFLD rats through reducing endoplasmic reticulum stress. BMC Complement Altern Med. 2019;19:228. https:\/\/doi.org\/10.1186\/s12906-019-2641-2.","journal-title":"BMC Complement Altern Med"},{"key":"1311_CR121","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12967-014-0236-8","volume":"12","author":"L Zhang","year":"2014","unstructured":"Zhang L, Xu J, Song H, Yao Z, Ji G. Extracts from salvia-nelumbinis naturalis alleviate hepatosteatosis via improving hepatic insulin sensitivity. J Transl Med. 2014;12:236. https:\/\/doi.org\/10.1186\/s12967-014-0236-8.","journal-title":"J Transl Med"},{"key":"1311_CR122","doi-asserted-by":"publisher","first-page":"992","DOI":"10.3748\/wjg.v24.i9.992","volume":"24","author":"Y-Y Zheng","year":"2018","unstructured":"Zheng Y-Y, Wang M, Shu X-B, Zheng P-Y, Ji G. Autophagy activation by jiang zhi granule protects against metabolic stress-induced hepatocyte injury. World J Gastroenterol. 2018;24:992\u20131003. https:\/\/doi.org\/10.3748\/wjg.v24.i9.992.","journal-title":"World J Gastroenterol"},{"key":"1311_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112825","volume":"149","author":"Y Cao","year":"2022","unstructured":"Cao Y, Shu X, Li M, Yu S, Li C, Ji G, et al. Jiangzhi granule attenuates non-alcoholic steatohepatitis through modulating bile acid in mice fed high-fat vitamin D deficiency diet. Biomed Pharmacother. 2022;149:112825. https:\/\/doi.org\/10.1016\/j.biopha.2022.112825.","journal-title":"Biomed Pharmacother"},{"key":"1311_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.833414","volume":"13","author":"C Li","year":"2022","unstructured":"Li C, Yu S, Li X, Cao Y, Li M, Ji G, et al. Medicinal formula huazhi-rougan attenuates non-alcoholic steatohepatitis through enhancing fecal bile acid excretion in mice. Front Pharmacol. 2022;13:833414. https:\/\/doi.org\/10.3389\/fphar.2022.833414.","journal-title":"Front Pharmacol"},{"key":"1311_CR125","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9739032","volume":"2022","author":"S Fan","year":"2022","unstructured":"Fan S, Zhou Z, Ye J, Li Y, Huang K, Ke X. Integration of lipidomics and transcriptomics reveals the efficacy and mechanism of qige decoction on NAFLD. Evid Based Complement Alternat Med. 2022;2022:9739032. https:\/\/doi.org\/10.1155\/2022\/9739032.","journal-title":"Evid Based Complement Alternat Med"},{"key":"1311_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156395","volume":"138","author":"S Fan","year":"2025","unstructured":"Fan S, Chen W, Li Y, Guo K, Tang H, Ye J, et al. Qige decoction attenuated non-alcoholic fatty liver disease through regulating SIRT6-PPAR\u03b1-mediated fatty acid oxidation. Phytomedicine. 2025;138:156395. https:\/\/doi.org\/10.1016\/j.phymed.2025.156395.","journal-title":"Phytomedicine"},{"key":"1311_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156439","volume":"138","author":"M Zhao","year":"2025","unstructured":"Zhao M, He Q, Shu X, Xu R, Zhang Z, Mou Y, et al. Zhuyu pill attenuates metabolic-associated fatty liver disease by regulating macrophage polarization through TLR4 signaling pathway. Phytomedicine. 2025;138:156439. https:\/\/doi.org\/10.1016\/j.phymed.2025.156439.","journal-title":"Phytomedicine"},{"key":"1311_CR128","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2147\/DDDT.S398808","volume":"17","author":"Y Pan","year":"2023","unstructured":"Pan Y, Feng X, Song W, Zhou X, Zhou Z, Chen G, et al. Effects and potential mechanism of zhuyu pill against atherosclerosis: network pharmacology and experimental validation. Drug Des Devel Ther. 2023;17:597\u2013612. https:\/\/doi.org\/10.2147\/DDDT.S398808.","journal-title":"Drug Des Devel Ther"},{"key":"1311_CR129","doi-asserted-by":"publisher","first-page":"29033","DOI":"10.1021\/acsomega.3c01955","volume":"8","author":"L Xu","year":"2023","unstructured":"Xu L, Xu K, Xiong P, Zhong C, Zhang X, Gao R, et al. Zhuyu pill alleviates nonalcoholic fatty liver disease by regulating bile acid metabolism through the gut-liver axis. ACS Omega. 2023;8:29033\u201345. https:\/\/doi.org\/10.1021\/acsomega.3c01955.","journal-title":"ACS Omega"},{"key":"1311_CR130","doi-asserted-by":"publisher","unstructured":"L D, J X, B L, Y D, R W, L Z, et al. Lingguizhugan decoction, a Chinese herbal formula, improves insulin resistance in overweight\/obese subjects with non-alcoholic fatty liver disease: A translational approach. Frontiers of medicine [Internet]. Front Med; 2022 [cited 2025 July 25];16. https:\/\/doi.org\/10.1007\/s11684-021-0880-3","DOI":"10.1007\/s11684-021-0880-3"},{"key":"1311_CR131","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01979-23","volume":"12","author":"L-P Chen","year":"2024","unstructured":"Chen L-P, Zhang L-F, Liu S, Hua H, Zhang L, Liu B-C, et al. Ling-gui-zhu-gan decoction ameliorates nonalcoholic fatty liver disease via modulating the gut microbiota. Microbiol Spectr. 2024;12:e0197923. https:\/\/doi.org\/10.1128\/spectrum.01979-23.","journal-title":"Microbiol Spectr"},{"key":"1311_CR132","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.693048","volume":"12","author":"A Shi","year":"2021","unstructured":"Shi A, Li T, Zheng Y, Song Y, Wang H, Wang N, et al. Chlorogenic acid improves NAFLD by regulating gut microbiota and GLP-1. Front Pharmacol. 2021;12:693048. https:\/\/doi.org\/10.3389\/fphar.2021.693048.","journal-title":"Front Pharmacol"},{"key":"1311_CR133","doi-asserted-by":"publisher","DOI":"10.1186\/s12906-020-2835-7","volume":"20","author":"S-H Shen","year":"2020","unstructured":"Shen S-H, Zhong T-Y, Peng C, Fang J, Lv B. Structural modulation of gut microbiota during alleviation of non-alcoholic fatty liver disease with gynostemma pentaphyllum in rats. BMC Complement Med Ther. 2020;20:34. https:\/\/doi.org\/10.1186\/s12906-020-2835-7.","journal-title":"BMC Complement Med Ther"},{"key":"1311_CR134","doi-asserted-by":"publisher","DOI":"10.3390\/nu16111782","author":"FY Jiang","year":"2024","unstructured":"Jiang FY, Yue SR, Tan YY, Tang N, Xu YS, et al. Gynostemma pentaphyllum extract alleviates NASH in mice: Exploration of inflammation and gut microbiota. Nutrients. 2024. https:\/\/doi.org\/10.3390\/nu16111782.","journal-title":"Nutrients"},{"key":"1311_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109258","author":"X Huang","year":"2019","unstructured":"Huang X, Chen W, Yan C, Yang R, Chen Q, Xu H, et al. Gypenosides improve the intestinal microbiota of non-alcoholic fatty liver in mice and alleviate its progression. Biomed Pharmacother. 2019. https:\/\/doi.org\/10.1016\/j.biopha.2019.109258.","journal-title":"Biomed Pharmacother"},{"key":"1311_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2022.154208","volume":"103","author":"Y-Y Tan","year":"2022","unstructured":"Tan Y-Y, Yue S-R, Lu A-P, Zhang L, Ji G, Liu B-C, et al. The improvement of nonalcoholic steatohepatitis by poria cocos polysaccharides associated with gut microbiota and NF-\u03baB\/CCL3\/CCR1 axis. Phytomedicine. 2022;103:154208. https:\/\/doi.org\/10.1016\/j.phymed.2022.154208.","journal-title":"Phytomedicine"},{"key":"1311_CR137","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1039\/d1fo03147c","volume":"13","author":"Y Lan","year":"2022","unstructured":"Lan Y, Sun Q, Ma Z, Peng J, Zhang M, Wang C, et al. Seabuckthorn polysaccharide ameliorates high-fat diet-induced obesity by gut microbiota-SCFAs-liver axis. Food Funct. 2022;13:2925\u201337. https:\/\/doi.org\/10.1039\/d1fo03147c.","journal-title":"Food Funct"},{"key":"1311_CR138","doi-asserted-by":"publisher","DOI":"10.1186\/s13568-024-01756-7","author":"Y Yan","year":"2024","unstructured":"Yan Y, Yuan H, Yang F, Na H, Yu X, Liu J, et al. Seabuckthorn polysaccharides mitigate hepatic steatosis by modulating the nrf-2\/HO-1 pathway and gut microbiota. AMB Express. 2024. https:\/\/doi.org\/10.1186\/s13568-024-01756-7.","journal-title":"AMB Express"},{"key":"1311_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116519","volume":"175","author":"B Li","year":"2024","unstructured":"Li B, Jiang X-F, Dong Y-J, Zhang Y-P, He X-L-S, Zhou C-L, et al. The effects of atractylodes macrocephala extract BZEP self-microemulsion based on gut-liver axis HDL\/LPS signaling pathway to ameliorate metabolic dysfunction-associated fatty liver disease in rats. Biomed Pharmacother. 2024;175:116519. https:\/\/doi.org\/10.1016\/j.biopha.2024.116519.","journal-title":"Biomed Pharmacother"},{"key":"1311_CR140","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1583711","volume":"16","author":"J Li","year":"2025","unstructured":"Li J, Zhou L, Xiao Z. Advances in the study of ophiopogon japonicus polysaccharides: structural characterization, bioactivity and gut microbiota modulation regulation. Front Pharmacol. 2025;16:1583711. https:\/\/doi.org\/10.3389\/fphar.2025.1583711.","journal-title":"Front Pharmacol"},{"key":"1311_CR141","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ijbiomac.2021.12.036","volume":"196","author":"L Zhang","year":"2022","unstructured":"Zhang L, Wang Y, Wu F, Wang X, Feng Y, Wang Y. MDG, an ophiopogon japonicus polysaccharide, inhibits non-alcoholic fatty liver disease by regulating the abundance of akkermansia muciniphila. Int J Biol Macromol. 2022;196:23\u201334. https:\/\/doi.org\/10.1016\/j.ijbiomac.2021.12.036.","journal-title":"Int J Biol Macromol"},{"key":"1311_CR142","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ijbiomac.2018.11.236","volume":"125","author":"Y Ru","year":"2019","unstructured":"Ru Y, Chen X, Wang J, Guo L, Lin Z, Peng X, et al. Polysaccharides from tetrastigma hemsleyanum diels et gilg: extraction optimization, structural characterizations, antioxidant and antihyperlipidemic activities in hyperlipidemic mice. Int J Biol Macromol. 2019;125:1033\u201341. https:\/\/doi.org\/10.1016\/j.ijbiomac.2018.11.236.","journal-title":"Int J Biol Macromol"},{"key":"1311_CR143","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1039\/d2fo03028d","volume":"14","author":"L Xiao","year":"2023","unstructured":"Xiao L, Xiong H, Deng Z, Peng X, Cheng K, Zhang H, et al. Tetrastigma hemsleyanum leaf extracts ameliorate NAFLD in mice with low-grade colitis via the gut-liver axis. Food Funct. 2023;14:500\u201315. https:\/\/doi.org\/10.1039\/d2fo03028d.","journal-title":"Food Funct"},{"key":"1311_CR144","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12866-025-04151-9","volume":"25","author":"A Zhou","year":"2025","unstructured":"Zhou A, Peng N, Yang L, Yang S, Wang J. Tanshinone regulated gut microbiota and TMAO to improve high-fat diet induced atherosclerosis in APOE-\/- mice. BMC Microbiol. 2025;25:432. https:\/\/doi.org\/10.1186\/s12866-025-04151-9.","journal-title":"BMC Microbiol"},{"key":"1311_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.118662","volume":"335","author":"L Zheng","year":"2024","unstructured":"Zheng L, Li B, Yuan A, Bi S, Puscher H, Liu C, et al. TFEB activator tanshinone IIA and derivatives derived from Salvia miltiorrhiza Bge. attenuate hepatic steatosis and insulin resistance. J Ethnopharmacol. 2024;335:118662. https:\/\/doi.org\/10.1016\/j.jep.2024.118662.","journal-title":"J Ethnopharmacol"},{"key":"1311_CR146","doi-asserted-by":"publisher","first-page":"1546119","DOI":"10.3389\/fphar.2025.1546119","volume":"16","author":"M Lv","year":"2025","unstructured":"Lv M, Zheng Y, Yuan M, Zhang E, Zheng M, Liu G, et al. Cassiae semen extract ameliorates hyperlipidemia in rats by modulating lipid metabolism and Fc\u03b3R-mediated immune regulation. Front Pharmacol. 2025;16:1546119. https:\/\/doi.org\/10.3389\/fphar.2025.1546119.","journal-title":"Front Pharmacol"},{"key":"1311_CR147","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/s42003-021-02883-8","volume":"4","author":"H Luo","year":"2021","unstructured":"Luo H, Wu H, Wang L, Xiao S, Lu Y, Liu C, et al. Hepatoprotective effects of cassiae semen on mice with non-alcoholic fatty liver disease based on gut microbiota. Commun Biol. 2021;4:1357. https:\/\/doi.org\/10.1038\/s42003-021-02883-8.","journal-title":"Commun Biol"},{"key":"1311_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109641","volume":"36","author":"W-L Sun","year":"2021","unstructured":"Sun W-L, Li X-Y, Dou H-Y, Wang X-D, Li J-D, Shen L, et al. Myricetin supplementation decreases hepatic lipid synthesis and inflammation by modulating gut microbiota. Cell Rep. 2021;36:109641. https:\/\/doi.org\/10.1016\/j.celrep.2021.109641.","journal-title":"Cell Rep"},{"key":"1311_CR149","doi-asserted-by":"publisher","first-page":"6632","DOI":"10.1021\/acs.jafc.4c07078","volume":"73","author":"W Sun","year":"2025","unstructured":"Sun W, Jia J, Liu G, Liang S, Huang Y, Xin M, et al. Polysaccharides extracted from old stalks of asparagus officinalis L. improve nonalcoholic fatty liver by increasing the gut butyric acid content and improving gut barrier function. J Agric Food Chem. 2025;73:6632\u201345. https:\/\/doi.org\/10.1021\/acs.jafc.4c07078.","journal-title":"J Agric Food Chem"},{"key":"1311_CR150","doi-asserted-by":"publisher","first-page":"1214577","DOI":"10.3389\/fmicb.2023.1214577","volume":"14","author":"X Peng","year":"2023","unstructured":"Peng X, Yi X, Deng N, Liu J, Tan Z, Cai Y. Zhishi daozhi decoction alleviates constipation induced by a high-fat and high-protein diet via regulating intestinal mucosal microbiota and oxidative stress. Front Microbiol. 2023;14:1214577. https:\/\/doi.org\/10.3389\/fmicb.2023.1214577.","journal-title":"Front Microbiol"},{"key":"1311_CR151","doi-asserted-by":"publisher","first-page":"1539277","DOI":"10.3389\/fcimb.2025.1539277","volume":"15","author":"L Fang","year":"2025","unstructured":"Fang L, Yi X, Shen J, Deng N, Peng X. Gut-brain axis mediated by intestinal content microbiota was associated with zhishi daozhi decoction on constipation. Front Cell Infect Microbiol. 2025;15:1539277. https:\/\/doi.org\/10.3389\/fcimb.2025.1539277.","journal-title":"Front Cell Infect Microbiol"},{"key":"1311_CR152","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.1005318","volume":"12","author":"C-R Bi","year":"2022","unstructured":"Bi C-R, Sun J-T, Du J, Chu L-Y, Li Y-J, Jia X-Y, et al. Effects of zhishi daozhi decoction on the intestinal flora of nonalcoholic fatty liver disease mice induced by a high-fat diet. Front Cell Infect Microbiol. 2022;12:1005318. https:\/\/doi.org\/10.3389\/fcimb.2022.1005318.","journal-title":"Front Cell Infect Microbiol"},{"key":"1311_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155776","volume":"131","author":"L Tian","year":"2024","unstructured":"Tian L, Chen J, Yang M, Chen L, Qiu J, Jiang Y, et al. Xiezhuo tiaozhi formula inhibits macrophage pyroptosis in the non-alcoholic fatty liver disease by targeting the SIRT1 pathway. Phytomedicine. 2024;131:155776. https:\/\/doi.org\/10.1016\/j.phymed.2024.155776.","journal-title":"Phytomedicine"},{"key":"1311_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.155111","author":"J Qiu","year":"2023","unstructured":"Qiu J, Chen L, Zhang L, Xu F, Zhang C, Ren G, et al. Xie zhuo tiao zhi formula modulates intestinal microbiota and liver purine metabolism to suppress hepatic steatosis and pyroptosis in NAFLD therapy. Phytomedicine. 2023. https:\/\/doi.org\/10.1016\/j.phymed.2023.155111.","journal-title":"Phytomedicine"},{"key":"1311_CR155","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1107071","author":"D Hui","year":"2023","unstructured":"Hui D, Liu L, Azami NL, Song J, Huang Y, Xu W, et al. The spleen-strengthening and liver-draining herbal formula treatment of non-alcoholic fatty liver disease by regulation of intestinal flora in clinical trial. Front Endocrinol. 2023. https:\/\/doi.org\/10.3389\/fendo.2022.1107071.","journal-title":"Front Endocrinol"},{"key":"1311_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.116988","volume":"318","author":"Y Li","year":"2024","unstructured":"Li Y, Zheng N, Gao X, Huang W, Wang H, Bao Y, et al. The identification of material basis of si miao formula effective for attenuating non-alcoholic fatty liver disease. J Ethnopharmacol. 2024;318:116988. https:\/\/doi.org\/10.1016\/j.jep.2023.116988.","journal-title":"J Ethnopharmacol"},{"key":"1311_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2021.153544","volume":"85","author":"R Han","year":"2021","unstructured":"Han R, Qiu H, Zhong J, Zheng N, Li B, Hong Y, et al. Si miao formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota. Phytomedicine. 2021;85:153544. https:\/\/doi.org\/10.1016\/j.phymed.2021.153544.","journal-title":"Phytomedicine"},{"key":"1311_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.117320","volume":"319","author":"G Deng","year":"2024","unstructured":"Deng G, Li J, Huang M, Li Y, Shi H, Wu C, et al. Erchen decoction alleviates the progression of NAFLD by inhibiting lipid accumulation and iron overload through caveolin-1 signaling. J Ethnopharmacol. 2024;319:117320. https:\/\/doi.org\/10.1016\/j.jep.2023.117320.","journal-title":"J Ethnopharmacol"},{"key":"1311_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.116811","volume":"317","author":"L Zhang","year":"2023","unstructured":"Zhang L, Chen N, Zhan L, Bi T, Zhou W, Zhang L, et al. Erchen decoction alleviates obesity-related hepatic steatosis via modulating gut microbiota-drived butyric acid contents and promoting fatty acid \u03b2-oxidation. J Ethnopharmacol. 2023;317:116811. https:\/\/doi.org\/10.1016\/j.jep.2023.116811.","journal-title":"J Ethnopharmacol"},{"key":"1311_CR160","doi-asserted-by":"publisher","DOI":"10.1186\/s12014-023-09442-9","volume":"20","author":"S Song","year":"2023","unstructured":"Song S, Zheng J, Zhao D, Zheng A, Zhu Y, Xu Q, et al. Quantitative proteomics analysis based on data-independent acquisition reveals the effect of shenling baizhu powder (SLP) on protein expression in MAFLD rat liver tissue. Clin Proteomics. 2023;20:55. https:\/\/doi.org\/10.1186\/s12014-023-09442-9.","journal-title":"Clin Proteomics"},{"key":"1311_CR161","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9701285","volume":"2020","author":"K Tang","year":"2020","unstructured":"Tang K, Deng Y, Zheng C, Nie H, Pan M, Chen R, et al. Prevention of nonalcoholic hepatic steatosis by shenling baizhu powder: involvement of adiponectin-induced inhibition of hepatic SREBP-1c. Oxid Med Cell Longev. 2020;2020:9701285. https:\/\/doi.org\/10.1155\/2020\/9701285.","journal-title":"Oxid Med Cell Longev"},{"key":"1311_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.03.158","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Tang K, Deng Y, Chen R, Liang S, Xie H, et al. Effects of shenling baizhu powder herbal formula on intestinal microbiota in high-fat diet-induced NAFLD rats. Biomed Pharmacother. 2018. https:\/\/doi.org\/10.1016\/j.biopha.2018.03.158.","journal-title":"Biomed Pharmacother"},{"key":"1311_CR163","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.7150\/ijbs.26086","volume":"14","author":"R Li","year":"2018","unstructured":"Li R, Li J, Huang Y, Li H, Yan S, Lin J, et al. Polydatin attenuates diet-induced nonalcoholic steatohepatitis and fibrosis in mice. Int J Biol Sci. 2018;14:1411\u201325. https:\/\/doi.org\/10.7150\/ijbs.26086.","journal-title":"Int J Biol Sci"},{"key":"1311_CR164","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.freeradbiomed.2016.11.037","volume":"102","author":"D Porras","year":"2017","unstructured":"Porras D, Nistal E, Mart\u00ednez-Fl\u00f3rez S, Pisonero-Vaquero S, Olcoz JL, Jover R, et al. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation. Free Radic Biol Med. 2017;102:188\u2013202. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2016.11.037.","journal-title":"Free Radic Biol Med"},{"key":"1311_CR165","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s10719-020-09949-5","volume":"37","author":"B Wang","year":"2020","unstructured":"Wang B, Niu J, Mai B, Shi F, Li M, Chen L, et al. Effects of extraction methods on antioxidant and immunomodulatory activities of polysaccharides from superfine powder gynostemma pentaphyllum makino. Glycoconj J. 2020;37:777\u201389. https:\/\/doi.org\/10.1007\/s10719-020-09949-5.","journal-title":"Glycoconj J"},{"key":"1311_CR166","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13070766","volume":"13","author":"M Parafati","year":"2024","unstructured":"Parafati M, La Russa D, Lascala A, Crupi F, Riillo C, Fotschki B, et al. Dramatic suppression of lipogenesis and no increase in beta-oxidation gene expression are among the key effects of bergamot flavonoids in fatty liver disease. Antioxidants. 2024;13:766. https:\/\/doi.org\/10.3390\/antiox13070766.","journal-title":"Antioxidants"},{"key":"1311_CR167","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.885039","volume":"13","author":"S-R Yue","year":"2022","unstructured":"Yue S-R, Tan Y-Y, Zhang L, Zhang B-J, Jiang F-Y, Ji G, et al. Gynostemma pentaphyllum polysaccharides ameliorate non-alcoholic steatohepatitis in mice associated with gut microbiota and the TLR2\/NLRP3 pathway. Front Endocrinol (Lausanne). 2022;13:885039. https:\/\/doi.org\/10.3389\/fendo.2022.885039.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1311_CR168","doi-asserted-by":"publisher","first-page":"9941","DOI":"10.1039\/d4fo02538e","volume":"15","author":"GE Lombardo","year":"2024","unstructured":"Lombardo GE, Navarra M, Cremonini E. A flavonoid-rich extract of bergamot juice improves high-fat diet-induced intestinal permeability and associated hepatic damage in mice. Food Funct. 2024;15:9941\u201353. https:\/\/doi.org\/10.1039\/d4fo02538e.","journal-title":"Food Funct"},{"key":"1311_CR169","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103291","volume":"75","author":"S Che","year":"2024","unstructured":"Che S, Qin B, Wu K, Zhu M, Hu H, Peng C, et al. EGCG drives gut microbial remodeling-induced epithelial GPR43 activation to lessen Th1 polarization in colitis. Redox Biol. 2024;75:103291. https:\/\/doi.org\/10.1016\/j.redox.2024.103291.","journal-title":"Redox Biol"},{"key":"1311_CR170","doi-asserted-by":"publisher","first-page":"9924","DOI":"10.1039\/d0fo02152k","volume":"11","author":"J Huang","year":"2020","unstructured":"Huang J, Li W, Liao W, Hao Q, Tang D, Wang D, et al. Green tea polyphenol epigallocatechin-3-gallate alleviates nonalcoholic fatty liver disease and ameliorates intestinal immunity in mice fed a high-fat diet. Food Funct. 2020;11:9924\u201335. https:\/\/doi.org\/10.1039\/d0fo02152k.","journal-title":"Food Funct"},{"key":"1311_CR171","doi-asserted-by":"publisher","DOI":"10.19540\/j.cnki.cjcmm.20200716.501","author":"CM Dai","year":"2021","unstructured":"Dai CM, Jin S, Zhang JZ. effect of dahuang zhechong pills combined with TACE on VEGF, MMP-2, TGF-\u03b21 and immune function of patients with primary liver cancer (blood stasis and collaterals blocking type). Zhongguo Zhong Yao Za Zhi. 2021. https:\/\/doi.org\/10.19540\/j.cnki.cjcmm.20200716.501.","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"1311_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/S1875-5364(22)60160-2","author":"CH Tian-Tian","year":"2022","unstructured":"Tian-Tian CH, Sha-Li DU, Shi-Jun WA. Dahuang zhechong pills inhibit liver cancer growth in a mouse model by reversing treg\/Th1 balance. Chin J Nat Med. 2022. https:\/\/doi.org\/10.1016\/S1875-5364(22)60160-2.","journal-title":"Chin J Nat Med"},{"key":"1311_CR173","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8560831","author":"X Duan","year":"2022","unstructured":"Duan X, Lv J, Jiang H, Zheng K, Chen Y. Inflammatory cytokines, adipocytokines, and Th17\/treg balance in patients with nonalcoholic fatty liver disease following administration of dahuang zhechong pills. Genet Res. 2022. https:\/\/doi.org\/10.1155\/2022\/8560831.","journal-title":"Genet Res"},{"key":"1311_CR174","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b20-00053","author":"J Yang","year":"2020","unstructured":"Yang J, Ma W, Mei Q, Song J, Shu L, et al. Protective effect of fuzi lizhong decoction against non-alcoholic fatty liver disease via anti-inflammatory response through regulating p53 and PPARG signaling. Biol Pharm Bull. 2020. https:\/\/doi.org\/10.1248\/bpb.b20-00053.","journal-title":"Biol Pharm Bull"},{"key":"1311_CR175","doi-asserted-by":"publisher","DOI":"10.1954\/j.cnki.cjcmm.2018.0094","author":"JY Yang","year":"2018","unstructured":"Yang JY, Shi ZH, Ma W, Tao DQ, Liu S, et al. effect of fuzi lizhong decoction in reducing liver injury of rats with non-alcoholic fatty liver via activating AMPK and suppressing NF-\u03baBp65 pathway. Zhongguo Zhong Yao Za Zhi. 2018. https:\/\/doi.org\/10.1954\/j.cnki.cjcmm.2018.0094.","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"1311_CR176","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1637701","volume":"2022","author":"J Yang","year":"2022","unstructured":"Yang J, Zhang Y, Yi H, Liao Y, Shu L, Zhang S, et al. Fuzi-lizhong decoction alleviates nonalcoholic fatty liver disease by blocking TLR4\/MyD88\/TRAF6 signaling. Evid Based Complement Alternat Med. 2022;2022:1637701. https:\/\/doi.org\/10.1155\/2022\/1637701.","journal-title":"Evid Based Complement Alternat Med"},{"key":"1311_CR177","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2020.112896","author":"Q Li","year":"2020","unstructured":"Li Q, Li M, Li F, Zhou W, Dang Y, Zhang L, et al. Qiang-gan formula extract improves non-alcoholic steatohepatitis via regulating bile acid metabolism and gut microbiota in mice. J Ethnopharmacol. 2020. https:\/\/doi.org\/10.1016\/j.jep.2020.112896.","journal-title":"J Ethnopharmacol"},{"key":"1311_CR178","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12906-019-2577-6","volume":"19","author":"M Zhu","year":"2019","unstructured":"Zhu M, Li M, Zhou W, Yang Y, Li F, Zhang L, et al. Qianggan extract improved nonalcoholic steatohepatitis by modulating lncRNA\/circRNA immune ceRNA networks. BMC Complement Altern Med. 2019;19:156. https:\/\/doi.org\/10.1186\/s12906-019-2577-6.","journal-title":"BMC Complement Altern Med"},{"key":"1311_CR179","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1397900","author":"Z Mou","year":"2024","unstructured":"Mou Z, Gong T, Wu Y, Liu J, Yu J. The efficacy and safety of dachaihu decoction in the treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis. Front Med. 2024. https:\/\/doi.org\/10.3389\/fmed.2024.1397900.","journal-title":"Front Med"},{"key":"1311_CR180","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.3748\/wjg.v25.i34.5105","volume":"25","author":"J-M Yang","year":"2019","unstructured":"Yang J-M, Sun Y, Wang M, Zhang X-L, Zhang S-J, Gao Y-S, et al. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease. World J Gastroenterol. 2019;25:5105\u201319. https:\/\/doi.org\/10.3748\/wjg.v25.i34.5105.","journal-title":"World J Gastroenterol"},{"key":"1311_CR181","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3109\/1061186X.2016.1157883","volume":"24","author":"W Liu","year":"2016","unstructured":"Liu W, Zhai Y, Heng X, Che FY, Chen W, Sun D, et al. Oral bioavailability of curcumin: problems and advancements. J Drug Target. 2016;24:694\u2013702. https:\/\/doi.org\/10.3109\/1061186X.2016.1157883.","journal-title":"J Drug Target"},{"key":"1311_CR182","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/bdd.2213","volume":"41","author":"D Wang","year":"2020","unstructured":"Wang D, Yu W, Cao L, Xu C, Tan G, Zhao Z, et al. Comparative pharmacokinetics and tissue distribution of cryptotanshinone, tanshinone IIA, dihydrotanshinone I, and tanshinone I after oral administration of pure tanshinones and liposoluble extract of salvia miltiorrhiza to rats. Biopharm Drug Dispos. 2020;41:54\u201363. https:\/\/doi.org\/10.1002\/bdd.2213.","journal-title":"Biopharm Drug Dispos"},{"key":"1311_CR183","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1517\/17425247.2014.945420","volume":"11","author":"SR Hwang","year":"2014","unstructured":"Hwang SR, Byun Y. Advances in oral macromolecular drug delivery. Expert Opin Drug Deliv. 2014;11:1955\u201367. https:\/\/doi.org\/10.1517\/17425247.2014.945420.","journal-title":"Expert Opin Drug Deliv"},{"key":"1311_CR184","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.125953","volume":"249","author":"Y Duan","year":"2023","unstructured":"Duan Y, Huang J, Sun M, Jiang Y, Wang S, Wang L, et al. Poria cocos polysaccharide improves intestinal barrier function and maintains intestinal homeostasis in mice. Int J Biol Macromol. 2023;249:125953. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.125953.","journal-title":"Int J Biol Macromol"},{"key":"1311_CR185","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1002\/ptr.8284","volume":"38","author":"X Rong","year":"2024","unstructured":"Rong X, Shen C, Shu Q. Interplay between traditional Chinese medicine polysaccharides and gut microbiota: the elusive \u201cpolysaccharides-bond-bacteria-enzyme\u201d equation. Phytother Res. 2024;38:4695\u2013715. https:\/\/doi.org\/10.1002\/ptr.8284.","journal-title":"Phytother Res"},{"key":"1311_CR186","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s13238-020-00784-w","volume":"12","author":"T-L Lin","year":"2021","unstructured":"Lin T-L, Lu C-C, Lai W-F, Wu T-S, Lu J-J, Chen Y-M, et al. Role of gut microbiota in identification of novel TCM-derived active metabolites. Protein Cell. 2021;12:394\u2013410. https:\/\/doi.org\/10.1007\/s13238-020-00784-w.","journal-title":"Protein Cell"},{"key":"1311_CR187","doi-asserted-by":"publisher","DOI":"10.1093\/nutrit\/nuaf227","author":"H Kong","year":"2025","unstructured":"Kong H, Han J, Meng X, Wang X, Zhang X-A. Chlorogenic acid-gut microbiota interactions: New insights for alleviating chronic diseases and health disorders. Nutr Rev. 2025. https:\/\/doi.org\/10.1093\/nutrit\/nuaf227.","journal-title":"Nutr Rev"},{"key":"1311_CR188","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1148737","volume":"14","author":"H Li","year":"2023","unstructured":"Li H, Xi Y, Xin X, Feng Q, Hu Y. Geniposide plus chlorogenic acid reverses non-alcoholic steatohepatitis via regulation of gut microbiota and bile acid signaling in a mouse model in vivo. Front Pharmacol. 2023;14:1148737. https:\/\/doi.org\/10.3389\/fphar.2023.1148737.","journal-title":"Front Pharmacol"},{"key":"1311_CR189","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s13318-019-00545-z","volume":"44","author":"VS Ipar","year":"2019","unstructured":"Ipar VS, Dsouza A, Devarajan PV. Enhancing curcumin oral bioavailability through nanoformulations. Eur J Drug Metab Pharmacokinet. 2019;44:459\u201380. https:\/\/doi.org\/10.1007\/s13318-019-00545-z.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1311_CR190","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.2147\/IJN.S194934","volume":"14","author":"G Yang","year":"2019","unstructured":"Yang G, Wu F, Chen M, Jin J, Wang R, Yuan Y. Formulation design, characterization, and in vitro and in vivo evaluation of nanostructured lipid carriers containing a bile salt for oral delivery of gypenosides. Int J Nanomedicine. 2019;14:2267\u201380. https:\/\/doi.org\/10.2147\/IJN.S194934.","journal-title":"Int J Nanomedicine"},{"key":"1311_CR191","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1875-5364(18)30041-4","volume":"16","author":"Z-H Jin","year":"2018","unstructured":"Jin Z-H, Qiu W, Liu H, Jiang X-H, Wang L. Enhancement of oral bioavailability and immune response of ginsenoside RH2 by co-administration with piperine. Chin J Nat Med. 2018;16:143\u20139. https:\/\/doi.org\/10.1016\/S1875-5364(18)30041-4.","journal-title":"Chin J Nat Med"},{"key":"1311_CR192","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.jhep.2019.08.005","volume":"71","author":"J Mouries","year":"2019","unstructured":"Mouries J, Brescia P, Silvestri A, Spadoni I, Sorribas M, Wiest R, et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol. 2019;71:1216\u201328. https:\/\/doi.org\/10.1016\/j.jhep.2019.08.005.","journal-title":"J Hepatol"},{"key":"1311_CR193","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1248\/bpb.30.847","volume":"30","author":"X Li","year":"2007","unstructured":"Li X, Wang G, Sun J, Hao H, Xiong Y, Yan B, et al. Pharmacokinetic and absolute bioavailability study of total panax notoginsenoside, a typical multiple constituent traditional Chinese medicine (TCM) in rats. Biol Pharm Bull. 2007;30:847\u201351. https:\/\/doi.org\/10.1248\/bpb.30.847.","journal-title":"Biol Pharm Bull"},{"key":"1311_CR194","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1224856","volume":"14","author":"F Wu","year":"2023","unstructured":"Wu F, Huang M, Zuo X, Xie R, Liu J, Ke J, et al. Osthole\/borneol thermosensitive gel via intranasal administration enhances intracerebral bioavailability to improve cognitive impairment in APP\/PS1 transgenic mice. Front Pharmacol. 2023;14:1224856. https:\/\/doi.org\/10.3389\/fphar.2023.1224856.","journal-title":"Front Pharmacol"},{"key":"1311_CR195","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1248\/bpb.b23-00444","volume":"46","author":"N Mori","year":"2023","unstructured":"Mori N, Oda K, Takakura H, Tanaka Y, Yokooji T, Murakami T. Comparison of berberine bioavailability between oral and rectal administrations in rats. Biol Pharm Bull. 2023;46:1639\u201342. https:\/\/doi.org\/10.1248\/bpb.b23-00444.","journal-title":"Biol Pharm Bull"},{"key":"1311_CR196","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.114021","author":"Y Lee","year":"2021","unstructured":"Lee Y, Kamada N, Moon JJ. Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome. Adv Drug Deliv Rev. 2021. https:\/\/doi.org\/10.1016\/j.addr.2021.114021.","journal-title":"Adv Drug Deliv Rev"},{"key":"1311_CR197","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jconrel.2024.04.026","volume":"370","author":"X Xiao","year":"2024","unstructured":"Xiao X, Zhang L, Ni M, Liu X, Xing L, Wu L, et al. Enhanced oral and pulmonary delivery of biomacromolecules via amplified transporter targeting. J Control Release. 2024;370:152\u201367. https:\/\/doi.org\/10.1016\/j.jconrel.2024.04.026.","journal-title":"J Control Release"},{"key":"1311_CR198","doi-asserted-by":"publisher","first-page":"913","DOI":"10.5650\/jos.ess20067","volume":"69","author":"SY Al-Okbi","year":"2020","unstructured":"Al-Okbi SY, Amin MA, Mohamed AEA, Edris AE, Sharaf OM, Mabrok HB, et al. Basil essential oil and its nanoemulsion mitigate non alcoholic steatohepatitis in rat model with special reference to gut microbiota. J Oleo Sci. 2020;69:913\u201327. https:\/\/doi.org\/10.5650\/jos.ess20067.","journal-title":"J Oleo Sci"},{"key":"1311_CR199","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.2147\/IJN.S452194","volume":"19","author":"J Lu","year":"2024","unstructured":"Lu J, Zeng Y, Zhong H, Guo W, Zhang Y, Mai W, et al. Dual-stimuli-responsive gut microbiota-targeting nitidine chloride-CS\/PT-NPs improved metabolic status in NAFLD. Int J Nanomedicine. 2024;19:2409\u201328. https:\/\/doi.org\/10.2147\/IJN.S452194.","journal-title":"Int J Nanomedicine"},{"key":"1311_CR200","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1954\/j.cnki.cjcmm.20210310.601","volume":"46","author":"L-J Cao","year":"2021","unstructured":"Cao L-J, Zhan S-Y, Ji X-Y, Zheng B-H, Ye C-Y, Chen Z-Y, et al. Research advance in multi-component pharmacokinetics of Chinese herbal extracts in recent five years. Zhongguo Zhong Yao Za Zhi. 2021;46:3270\u201387. https:\/\/doi.org\/10.1954\/j.cnki.cjcmm.20210310.601.","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"1311_CR201","doi-asserted-by":"publisher","DOI":"10.1016\/j.trac.2025.118269","volume":"189","author":"Elsevier","year":"2025","unstructured":"Elsevier. Recent advances in traditional Chinese medicine metabolism: sample pre-treatment, MS-oriented analytical strategies and typical applications. TrAC Trends Anal Chem. 2025;189:118269. https:\/\/doi.org\/10.1016\/j.trac.2025.118269.","journal-title":"TrAC Trends Anal Chem"},{"key":"1311_CR202","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.3390\/nu12092499","volume":"12","author":"B Scazzocchio","year":"2020","unstructured":"Scazzocchio B, Minghetti L, D\u2019Archivio M. Interaction between gut microbiota and curcumin: a new key of understanding for the health effects of curcumin. Nutrients. 2020;12:2499. https:\/\/doi.org\/10.3390\/nu12092499.","journal-title":"Nutrients"},{"key":"1311_CR203","doi-asserted-by":"publisher","DOI":"10.5394\/jmnp.2025.100014","author":"A Gupta","year":"2025","unstructured":"Gupta A, Kumari K, Hasan F, Kumar V, Kumar P, Gupta A, et al. Herb-drug interactions: a critical exploration in modern healthcare practices. JMNP. 2025. https:\/\/doi.org\/10.5394\/jmnp.2025.100014.","journal-title":"JMNP"},{"key":"1311_CR204","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384. https:\/\/doi.org\/10.1002\/hep.28431.","journal-title":"Hepatology"},{"key":"1311_CR205","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108728","volume":"264","author":"M Li","year":"2024","unstructured":"Li M, Wang Y, Chen Y, Dong L, Liu J, Dong Y, et al. A comprehensive review on pharmacokinetic mechanism of herb-herb\/drug interactions in Chinese herbal formula. Pharmacol Ther. 2024;264:108728. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108728.","journal-title":"Pharmacol Ther"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-025-01311-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-025-01311-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-025-01311-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:02:47Z","timestamp":1767999767000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13020-025-01311-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":205,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1311"],"URL":"https:\/\/doi.org\/10.1186\/s13020-025-01311-x","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants agree to publish.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}